Role of GnRH agonists prior to endoscopic surgical treatment of fibroids

Uterine fibroids are the most common benign tumors found in women of reproductive age and their treatment is mainly by surgery, especially if they are symptomatic. Since the boom in endoscopy, many reports conclude that treatment of fibroids can be performed safely by laparoscopy or hysteroscopy. The development of GnRH analogues is not only a breakthrough in the field of obstetrics and gynecology, but a major leap forward in the treatment of various hormone-dependent diseases in general medicine. Recently GnRH agonistic analogues have been applied to treat various gynecological conditions, such as uterine leiomyomas, endometriosis, dysfunctional uterine bleeding, hyperandrogenism (polycystic ovaries) and infertility, cancer and precocious puberty. GnRH agonist administration prior to the surgical approach to uterine fibroids has a positive role in the management of these tumors, because—despite the expense—they reduce fibroid and uterine volume and intraoperative blood loss and they increase hemoglobin levels prior to surgical intervention. GnRH agonists can be used preoperatively in the field of endoscopic surgery in selected cases, especially in hysteroscopic surgery. However, their exact role in the laparoscopic management of fibroids needs further evaluation. Similar content being viewed by others

Buttram VC Jr, Reiter RC (1981) Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 36:433–445 Vollenhoven BJ, Lawrence AS, Healy DL (1990) Uterine fibroids: a clinical review. Br J Obstet Gynaecol 97:285–295 Craner SF, Patel A (1990) The frequency of uterine leiomyomas. Am J Clin Pathol 94:435–438 Bonney V (1931) The technique and results of myomectomy. Lancet 1:171–177 Hanks HT (1988) Trans N Y Obstet Soc 58–77 Fergusson ILC, Taylor RW, Watson JM (1982) Records and curiosities in obstetrics and gynaecology. Bailliere Tindall, London Wallach EE, Vu KK (1995) Myomata uteria and infertility. Obstet Gynecol Clin North Am 11:791–799 Cramer DW (1992) Epidemiology of myomas. Semin Reprod Endocrinol 10:320 Barbieri RL, Andersen J (1992) Uterine leiomyomas; the somatic mutation theory. Semin Reprod Endocrinol 10:301 Townsed DE, Sparkes RS, Baluda MC et al (1970) Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 107:1168–1173 Mashal RD, Fejzo ML, Friedman AJ et al (1994) Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 11:1–6 Speroff L, Glass RH, Kase NG (1999) Clinical gynaecologic endocrinology and infertility, 6th edn. Lippincott Williams & Wilkins, Baltimore, MD Fejzo MS, Yoon SJ, Montgomery KT et al (1995) Identification of a YAC spanning the translocation breakpoints in uterine leiomyomata, pulmonary chondroid hamartoma, and lipoma: physical mapping of the 12q14-q15 breakpoint region in uterine leiomyomata. Genomics 25:265–271 Rein MS, Friedman AJ, Barbieri RL et al (1991) Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 77:923–926 Brosens I, Johannisson E, Dal Cin P et al (1996) Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal and gonadotropin-releasing hormone agonist-treated females. Fertil Steril 66:376–379 Schlaff WD, Zerhouni EA, Huth JAM et al (1989) A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obset Gynecol 74:856–862 Otubu JA, Buttram VC, Besch NF, Besch PK (1982) Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 143:130 Rein MS, Friedman AJ, Stuart JM et al (1990) Fibroid and myometrial steroid receptors in women treated with the gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 53:1018–1023 Kawagushi K, Fujii S, Konishi I et al (1989) Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637 Tiltman AJ (1985) The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4:89 Uemura T, Mori J, Yoshimura Y et al (1991) Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas. Asia Oceania J Obstet Gynaecol 17:315–320 Brandon DD, Bethea CL, Strawn EY et al (1993) Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169:78 Murphy AA, Kettel LM, Morales AJ et al (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76:513 Friedman AJ, Rein MS, Pandian MR et al (1990) Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo. Fertil Steril 53:250–253 Rein MS, Friedman AJ, Pandian MR et al (1990) The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol 76:388–394 Yeh J, Rein M. Nowak R (1991) Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril 56:997–1000 Friedman AJ, Daly M, Juneau-Norcross M et al (1992) Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 58:413–5 Mais V, Ajossa S, Guerriero S et al (1996) Laparoscopic versus abdominal myomectomy: a randomized trial to evaluate benefits in early outcome. Am J Obstet Gynecol 174:654–658 Semm K, Mettler L (1980) Technical progress in pelvic surgery via operative laparoscopy. Am J Obstet Gynecol 138:121–127 Nezhat C, Nezhat F, Silfen SL et al (1991) Laparoscopic myomectomy. Int J Fertil 36:175–280 Hasson HM, Rotman C, Rana N et al (1992) Laparoscopic myomectomy. Obstet Gynecol 80:884–888 Duduisson JB, Lecuru F, Foulot H et al (1991) Myomectomy by laparoscopy: a preliminary report of 43 cases. Fertil Steril 56:827–830 Niesert S (1996) Leuproelin—an exciting development in the treatment of gynaecological disorders. Hormone Ther Obstet Gynecol 1:4–9 Reissman T, Felderbaum R, Diedrich K, Engel J et al (1995) Development and applications of LHRH antagonists in the treatment of infertility: an overview. Hum Reprod 10:1974–1979 Tzafettas JM (2000) Current and potential application of GnRH agonists in gynecologic practice. Ann N Y Acad Sci 900:435–443 Stewart EA, Friedman AJ (1992) Steroidal treatment of myomas: Preoperative and long-term medical therapy. Semin Reprod Endocrinol 10:344 Seracchioli R, Venturoli S, Colombo FM et al (2003) GnRH agonist treatment before total laparoscopic hysterectomy for large uteri. J Am Assoc Gynecol Laparosc 10:316–319 Lethaby A, Vollenhoven B, Sowter M (2004) Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids (Cohrane review). In: Cochrane Library, Issue 3, John Wiley, Chichester, UK Wang PH, Yang AH, Yuan CC et al (1998) Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings. Zhonghua Yi Xue Za Zhi (Taipei) 61:625–9 Matta WH, Stabile I, Shaw RW et al (1988) Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 49:1083–5 Shaw RW (1989) Mechanism of LHRH analogue action in uterine fibroids. Horm Res 32:150–153 Reinsch RC, Murphy AA, Morales AJ et al (1994) The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, ramdomised study. Am J Obstet Gynecol 170:1623–1628 Zullo F, Pellicano M, Di Carlo C et al (1998) Ultrasonographic prediction of the efficacy of GnRH agonist therapy before laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 5:361–366 Aleem FA, Predanic M (1995) The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography. Gynecol Endocrinol 9:253–258 Mizutani T, Sugihara A, Nakamuro K et al (1998) Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 83:1253–1255 Kalir T, Goldstein M, Dottino P et al (1998) Morphometric and electron microscopic analyses of the effects of gonadotropin-releasing hormone agonists of uterine leiomyomas. Arch Pathol Lab Med 122:442–446 Higasijima T, Kataoka A, Nishida T et al (1996) Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 68:169–173 Deligdisch L, Hirschmann S, Altchek A (1997) Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril 67:837–841 Demopoulos RI, Jones KY, Mittal KR et al (1997) Histology of leiomyomata in patients treated with leuprolide acetate. Int J Gynecol Pathol 16:131–137 Berbieri RL, Dilena M, Chumas J et al (1993) Leuprolide acetate depot decreases the number of nucleolar organizer regions in uterine leiomyomata. Fertil Steril 60:569–570 Vu K, Greenspan DL, Wu TC et al (1998) Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist treated uterine leiomyomas. Hum Pathol 29:359–363 Kawamura N, Ito F, Ichimura T et al (1997) Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment. Fertil Steril 68:632–636 Oguchhi O, Mori A, Kobayashi Y et al (1995) Prediction of histopathologic features and proliferative activity of uterine leiomyoma by magnetic resonance imaging prior to GnRH analogue therapy: Correlation between T2-weighted images and effect of GnRH analogue. J Obstet Gynecol 21:107–117 Campo S, Garcea N (1999) Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod 14:44–850 Palomba S, Pellicano M, Affinito P et al (2001) Effectiveness of short-term administration of tibilone plus gonadotropin—releasing hormone analogue on the surgical outcome of laparoscopic myomectomy. Fertil Steril 75:429–433 Balasch J, Manau D, Mimo J et al (1995) Trial of routine gonadotropin-releasing hormone agonists treatment before abdominal hysterectomy for leiomyoma. Acta Obstet Gynecol Scand 74:562–565 Sutton C (2000) Uterine fibroids: a critical review of currently available treatment methods. Gynaecol Endosc 9:345–350 Acien P, Quereda F (1996) Abdominal myomectomy: results of a simple operative technique. Fertil Steril 65:41–51 Dubuisson JB, Fauconnier A, Bakkaki-Fard K, Chapron C (2000) Laparoscopic myomectomy: a current view. Hum Reprod Update 6:588–594 Sinha R, Hedge A, Warty N, Patil N (2003) Laparoscopic excision of very large myomas. J Am Assoc Gynecol Laparosc 10:461–468 Park K, Chung JE, Kim JY, Kim YT (1999) Endoscopic management of uterine myoma. Yonsei Med J 40:583–588 Parker WH, Rodi IA (1994) Patient selection for laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 2:23–6 Dubuisson J, Fauconnier A, Fourchotte V et al (2001) Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod 16:1726–1731 Nezhat FR, Roemisch M, Nezhat CH et al (1998) Recurrence rate after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 5:237–240 Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB (2000) Recurrence of leiomyomata after myomectomy. Hum Reprod Update 6:595–602 Fedele L, Vercellini P, Bianchi S et al (1990) Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynecol 97:393–396 Rosseti A, Sizzi O, Soranna L et al (2001) Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 16:770–774 Friedman AJ, Hoffman DI, Browneller RW et al (1991) Treatment of leiomyomata uteri with leucoprolide acetate depot: a double blind, placebo-controlled, multicenter study. Obstet Gynecol 77:720–725 Sudik R, Husch K, Steller J, Daume E (1995) Fertility and pregnancy outcome after myomectomy in sterility patients. Eur J Obstet Gynecol Reprod Biol 65:209–214 Doritot V, Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K (2001) Recurrence of leiomyomata after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 8:495–500 Neuwirth RS, Amin HK (1976) Excision of submucous fibroids with hysteroscopic control. Am J Obstet Gynecol 126:95 Valle RF (1990) Hysteroscopic removal of submucous leiomyomas. J Gynecol Surg 6:89–96 Donnez J, Gillerot S, Bourgonjon D et al (1990) Neodymium: YAG laser hysteroscopy in large submucous fibroids. Fertil Steril 54:999–1003 Clatk TJ, Mahajan D, Sunder P Gupta JK (2002) Hysteroscopic treatment of symptomatic submucous fibroids using a bipolar intrauterine system: a feasibility study. Eur J Obstet Gynecol Reprod Biol 100:237–242 Slade RJ, McCallum KA, Ellis JD (1993) Endometrial resection after GnRH analogue therapy—a possible new treatment for fibromata. J Obstet Gynecol 13:69–70 Donnez J, Mathieu PE, Bassil S et al (1996) Laparoscopic myomectomy today. Fibroids: management and treatment: the state of the art. Hum Reprod 11:1837–1840 Mencaglia L, Tantini C (1993) GnRH agonist analogs and hysteroscopic resection of myomas. Int J Gynecol Obstet 43:285–288 Donnez J, Polet R, Anaf V et al (1995) Treatment of dysfunctional bleeding and fibroids by advanced endoscopic techniques with the Nd:YAG laser: from the present to the future. Baillieres Clin Obstet Gynaecol 9:329–345 Perino A, Chianchiano N, Petronio M et al (1993) Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study. Fertil Steril 59:507–510 Friedman AJ, Lobel SM, Rein MS et al (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 163:1114–1119 Franssen AMHW, Willemensen WNP, Corbey RS et al (1991) Subcutaneous injection or infusion of gonadotropin-releasing hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata. Eur J Obstet Gynecol Repro Biol 40:221–228 Letterie JS, Stevenson D, Shah A (1991) Recurrent anaphylaxis to a depot form of a GnRH analogue. Obstet Gynecol 78:943 Cheung T-H, Wing-Kit Lo K, Wai-Kei Lam C et al (2000) A crossover study of triptorelin and leuproreline acetate. Fertil Steril 74:299–305 Friedman AJ (1989) Treatment of leiomyomata uteri with short term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 51:526–528 Palomba S, Affinito P, Di Carlo C et al (1999) Long-term administration of tibolone plus gonadotrophin-releasing hormone agonist for the treatment of uterine leiomyomas: Effectiveness and effects on vasomotor symptoms, bone mass and lipid profiles. Fertil Steril 76:216–217 Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Theodoridis, T.D., Tarlatzis, B.C. & Bontis, J.N. Role of GnRH agonists prior to endoscopic surgical treatment of fibroids. Eur Clinics Obstet Gynecol 1, 12–18 (2005). https://doi.org/10.1007/s11296-004-0008-8 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s11296-004-0008-8